The discovery of the autoimmune regulator (AIRE) protein and the delineation of its critical contributions in the establishment of central immune tolerance has significantly expanded our understanding of the immunological mechanisms that protect from the development of autoimmune disease. The parallel identification and characterization of patient cohorts with the monogenic disorder autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is typically caused by biallelic AIRE mutations, has underscored the critical contribution of AIRE in fungal immune surveillance at mucosal surfaces and in prevention of multiorgan autoimmunity in humans. In this review, we synthesize the current clinical, genetic, molecular and immunological knowledge derived from basic studies in Aire-deficient animals and from APECED patient cohorts. We also outline major advances and research endeavors that show promise for informing improved diagnostic and therapeutic approaches for patients with APECED.
| INTRODUC TI ON
Immunological recognition of self and non-self is of paramount importance to the body's ability to harness the appropriate defense against invading pathogens while simultaneously avoiding a misdirected autoimmune response. The autoimmune regulator (AIRE) protein is a transcriptional regulator that plays a critical role in selftolerance through orchestrating the promiscuous gene expression of tissue-specific antigens (TSAs) in a subset of medullary thymic epithelial cells (mTECs). 1 Naive thymocytes that recognize these TSAs with high affinity undergo apoptosis in a process referred to as negative selection. [2] [3] [4] Dysfunction of this process allows selfreactive T cells to escape into the periphery resulting in autoimmune destruction of certain tissues. 5 Consonant with the crucial role of APECED/APS-1 is a rare monogenic disorder characterized by development of multiorgan autoimmunity that targets several endocrine and non-endocrine tissues, and susceptibility to a "signature" infectious disease, chronic mucocutaneous candidiasis (CMC), which manifests with chronic, recurrent and severe infections of the mucous membranes, skin and/or nails by the commensal yeast fungus Candida. [6] [7] [8] [9] Since the initial clinical descriptions of APECED/ APS-1 in the medical literature in between 1929 and 1943 [10] [11] [12] and the subsequent discovery of its genetic etiology via heroic positional cloning efforts by the Finnish-German Consortium and Dr. Shimizu's research group in 1997, 13, 14 there have been significant advances in our understanding of this rare disease. In this review, we discuss the broad clinical implications of AIRE deficiency on autoimmunity, our understanding of the molecular and genetic mechanisms that play a role in the pathogenesis of APECED, and how these findings may guide therapeutic strategies based on the evaluation and treatment of ~120 APECED patients at the NIH Clinical Center in the past 5 years.
| PRE VALEN CE
APECED exhibits its highest prevalence amongst certain historically isolated populations such as Persian Jews (1:9000), Sardinians
(1:14 000) and Finns (1:25 000), [14] [15] [16] [17] [18] which display enrichment for corresponding founder "signature" AIRE mutations; indeed, the missense mutation Y85C, the nonsense mutation R139X, and the nonsense mutation R257X are commonly observed and are somewhat specific for these patient populations, respectively. The prevalence of APECED has also been estimated in other countries such as Slovenia (1:43 000), Norway (1:80 000) and Poland (1:129 000). [19] [20] [21] The estimated prevalence of APECED in most other countries is thought to be in the range 1:80 000-200 000, although a systematic effort to accurately calculate country-specific prevalence rates is missing thus far.
| D IAG NOS IS OF THE SUS PEC TED APECED PATIENT
The diagnosis of APECED is established by the presence of any two clinical manifestations from the classical triad of CMC, hypoparathyroidism and adrenal insufficiency (Addison's disease), although the diagnosis can be based on the development of only one of the classic triad manifestations in a child who's sibling already carries the diagnosis of APECED. 6, 22, 23 Nonetheless, recent work from our group and others has underscored the much broader and deeper clinical phenotype of APECED patients compared to that previously recognized. [7] [8] [9] 18, 24 Indeed, highlighting the vast phenotypic diversity of the disease, greater than 30 distinct manifestations can be seen, with more than 25 of those involving non-endocrine organs (Lionakis, unpublished data). 8, 9 Specifically, beyond the classical triad components of APECED, patients may also exhibit varying frequencies of urticarial eruption, enamel hypoplasia, intestinal malabsorption, autoimmune hepatitis, autoimmune pneumonitis, autoimmune gastritis, Sjogren's-like syndrome, B12 deficiency, vitiligo, keratoconjuctivits, alopecia, type-1 diabetes, tubulointerstitial nephritis and asplenia, among others (Table 1 , Figure 1 ). [7] [8] [9] [18] [19] [20] [25] [26] [27] [28] [29] [30] Of interest, some of the above clinical manifestations, particularly those that target the skin, the lungs, the salivary glands, the stomach, the intestine, and the liver appear to be significantly enriched among American APECED patients compared to their frequency reported in European patient cohorts. Whether this phenotypic discrepancy is explained by genetic, environmental, microbiome, and/or other differences among the various patient cohorts or it is the result of the deeper systematic phenotyping that was recently performed in American APECED patients remains to be elucidated by future studies.
Unfortunately, the vast majority of APECED patients will develop several other disease components before reaching a classic diagnostic dyad, which would then raise suspicion for APECED. On average, patients suffer from more than five manifestations and up to 20 conditions have been reported per individual. 7, 8, 31 Given the heterogenous presentation, the disease often goes unrecognized leading to an unfortunate delay in the diagnosis. Within an American cohort that we recently evaluated and reported at the National Institutes of Health, the mean age of achieving a classic diagnostic dyad of APECED was over 7 years of age. 8 Strikingly, only 20% of those patients developed their first two consecutive disease manifestations among the classic triad of manifestations. Instead, 80% of the patients within our cohort developed a median of three non-triad manifestations before developing a classic diagnostic dyad, which led to prolonged periods of diagnostic uncertainty and development of additional (often irreversible) autoimmune sequelae before a diagnostic dyad was reached and the APECED diagnosis was suspected and eventually established.
Among the early common manifestations that affected children in North and South America before the development of a classic diagnostic dyad, three manifestations were particularly prominent:
urticarial eruption, enamel hypoplasia, and intestinal malabsorption.
Less often, autoimmune pneumonitis, autoimmune hepatitis or keratoconjuctivitis were noted. 8 The urticarial eruption appeared as frequent as CMC as the first manifestation in the American APECED cohort; it is typically a non-pruritic maculopapular rash in the extremities and the torso ( Figure 2 ) that is not clearly associated with viral illness, vaccination or other inciting event, and is only infrequently accompanied by fever. The eruption is typically self-limited lasting days or weeks, and recurrences are frequent within the first 2-3 years of life. Histologically, the eruption features a characteristic picture of mixed myeloid and lymphoid cell infiltration, occasionally extending to the fat to cause panniculitis, but without vasculitis typically.
Importantly, recognition of these additional manifestations that appear early in the course of the disease may help to reduce diagnostic delay and allow for prompt institution of therapy (see below).
On the basis of the above findings, we proposed expanded diagnostic criteria for American APECED patients by incorporation of the adjunct diagnostic triad of urticarial eruption, enamel hypoplasia and intestinal malabsorption to the classic triad criteria (Figure 3 ).
Upon such incorporation, a diagnostic dyad within these expanded diagnostic criteria would have been reached with a mean of 4 years earlier compared to reaching a diagnostic dyad within the classic diagnostic criteria. This earlier diagnosis would have been reached before development of life-threatening Addisonian crisis or hypocalcemic seizures in approximately half of the affected patients.
We have now validated these expanded diagnostic criteria in other independent patient datasets enrolled consecutively in the 
| CLINI C AL MANIFE S TATI ON S OF APECED PATIENTS
APECED patients present with a characteristic combination of (a) a single consistent infectious disease manifestation, CMC, and (b) autoimmunity that affects several endocrine and non-endocrine tissues.
There is significant patient to patient variability in the phenotypic ex- 
| Infectious manifestations

| Endocrine autoimmune manifestations
Endocrine autoimmune disease is the hallmark of APECED syndrome, as the acronym indicates. Hypoparathyroidism, which typically develops earlier than any other endocrinopathy, and adrenal insufficiency are the most common endocrine manifestations.
Additional endocrinopathies that develop with lower frequencies include hypothyroidism, primary ovarian or testicular failure, growth hormone deficiency, and hypopituitarism. Some of these endocrine manifestations are associated with the presence of corresponding organ-specific AAbs, although these AAbs do not always predict the development of the corresponding endocrinopathy at the individual patient level (see below; Table 2 ). Of interest, type I diabetes is an uncommon complication of patients with APECED, which typically occurs later in adolescence or adulthood in ~5%-10% of patients.
| Non-endocrine autoimmune manifestations
As mentioned earlier, non-endocrine autoimmune manifestations have recently been recognized as common disease components in certain cohorts of patients with APECED. Urticarial eruption, as mentioned above, is a characteristic early common feature in American sclerosis. 57 The immunological shadow of peripheral tissue antigens that Aire projects in the thymus is limited. 58 It is likely that other transcription factors expressed in the thymus, such as Fezf2 or others, may guide the expression of a complementary array of tissue specific antigens and may confer tolerance to specific tissues. Indeed, studies using Foxn1-Cre+Fezf2fl/fl mice revealed a different phenotype than Aire -/-models with inflammatory infiltration of the lung, liver, kidney, stomach, small intestine, salivary gland, testis, and brain, some of which (i.e., kidney, brain) are not seen in Aire-deficient mice. 
| Ectodermal dystrophy manifestations
Several manifestations of APECED patients have been attributed to ectodermal dystrophy, as the acronym implies. The most common such manifestation is enamel hypoplasia, which manifests early in the course of the disease and its recognition by pediatric dentists 
| AIRE S TRUC TURE
The AIRE gene is located in the long arm of chromosome 21 at po- genes. 64 The two PHD zinc fingers suggest that AIRE regulates transcription epigenetically through interaction with unmethylated lysine 4 on histone H3 (H3K4me0). 65 Hence, PHD-1 is critical for the transcription-transactivation activity of AIRE and was shown to be essential for preventing autoimmunity in transgenic mouse models. [66] [67] [68] In addition to these four subunits, there are two NLS (nuclear localization signal) regions implicated in nuclear transport as well as four LXXLL motifs, which mediate interactions with other LXXLL-containing proteins and may play a role in the homo-oligomerization of AIRE. 61 
| AIRE E XPRE SS I ON AND FUN C TI ON
| mTECs and CD4 + T cells
Shortly following the discovery that biallelic mutations in the AIRE gene result in APECED in 1997, 13, 14 Anderson and colleagues revealed in 2002 that Aire is predominately expressed within a subset of epithelial cells of the medullary thymus, 58 although Aire expression has now been shown in extrathymic Aire-expressing cells (eTACs), and B cell and dendritic cell populations (see below). [69] [70] [71] [72] These specialized cells, referred to as mTECs, facilitate ectopic expression of thousands of self-peptides, where they are presented to developing thymocytes (T cells) via major histocompatibility complex (MHC) antigens. 61, 73, 74 T cells that bind to these self-peptide antigens exceeding an appropriate affinity threshold undergo clonal deletion, thereby preventing their release into circulation. 4 In the absence of AIRE, this process is defective, self-peptides are not ex- 
| B cells and AAbs
Aire −/− auto-reactive B cells have also been suggested to be drivers of organ-specific autoimmunity in mice, predominantly in the lungs, although another study revealed a broader organ distribution for the role of Aire-deficient B cells in autoimmunity. 76, 90 In fact, APECED patients exhibit a significant expansion in the autoreactive BPIFB1 and KCNRG for autoimmune lung disease, 26, 97 and others (Table 2) . 8, [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] Future work will be needed to uncover other autoantigens that may provide explanation for the pathogenesis of the autoimmune attack in the spleen, salivary and lacrimal glands, nails, and skin of APECED patients.
In addition to tissue-specific autoantibodies, as mentioned earlier, nearly all patients with APECED produce autoantibodies directed against type I interferons, which have early diagnostic utility. 33, 35 Of note, the occurrence of AAbs against GAD65 (glutamic acid decarboxylase) in the majority of APECED patients 8 
| eTACs
Besides Aire-expressing mTECs, the identification of eTACs within 
| AIRE PARTNER S AND REG UL ATI ON
AIRE appears to be tightly regulated with recent identification of important enhancer elements activated by nuclear factor-κB (NF-κB) signaling that are necessary for AIRE's expression. For example, the conserved non-coding sequence 1 (CNS1) proximal to the Aire promoter is a cis-regulatory element critically important for AIRE expression in mTECs. 118, 119 
| AIRE MUTATI ON S IN APECED PATIENTS
APECED follows an autosomal recessive pattern of inheritance with more than 100 AIRE mutations having been reported throughout the entire gene. 127 Depending on the patient cohort, homozygous or compound heterozygous AIRE mutations are seen more often. Recently, dominant-negative AIRE mutations involving the SAND or PHD-1 domains have also been identified, some of which have a relatively high frequency in the general population (up to 1 in 1000).
These patients present with much less severe APECED-like disease, often with later onset, manifested by limited organ involvement such as pernicious anemia or vitiligo or an isolated endocrinopathy; AAbs are not always positive in these patients. [133] [134] [135] [136] These findings indicate that such dominant-negative AIRE variants may modulate the phenotypic expression of common organ-specific autoimmune diseases. In that light, AIRE variants along with other risk loci were recently reported to be associated with Addison's disease. 137 Last, an intriguing recent report by the Matsumoto lab indicated that overexpression of human AIRE in mice resulted in the development of a paradoxical muscle-specific autoimmune disease, associated with impaired maturation of mTECs and defective expression of Airedependent TSAs. 138 These data both illustrate the importance for tight control of AIRE expression and function and raise the possibility that gain-of-function AIRE genetic variants may exist in humans, perhaps having a potential association with organ-specific autoimmune diseases such as polymyositis or dermatomyositis.
| MANAG EMENT OF APECED PATIENTS
As the onset of symptoms, disease severity and progression, and number of disease manifestations are highly variable amongst patients the majority of patients are best served by a multidisciplinary team of providers at a tertiary care-level facility. At the initial visit, healthcare providers should perform a comprehensive evaluation with special attention to involvement of tissue sites reported. 8 The integration of specialists from immunology, infectious disease, endocrinology, pulmonology, hepatology, gastroenterology, dermatology, nephrology, and dentistry provides the best possible evaluation for the individual patient. Subsequent visits over time should continue surveillance for the development of other disease manifestations and involvement of additional organ systems. The principles of evaluation and management of the APECED patients include treatment of CMC and other infectious complications, hormone, and/or electrolyte replacement for irreversible endocrinopathies, and immunomodulation for non-endocrine end-organ disease. 
| CMC and other infectious complications
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